Fed Circ to rehear $235m ‘skinny label’ case

The US Court of Appeals for the Federal Circuit has agreed to reconsider its precedential ruling against Teva Pharmaceuticals for producing a generic hypertension and heart failure treatment, according to a Bloomberg Law report.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Actavis and Teva sued over narcotic addiction generic

1 March 2017 Speciality pharmaceutical company Orexo has filed a complaint against Actavis and its parent company Teva for infringing patents protecting Orexo’s Suboxone and Subutex.

Generics

Amgen, Teva to face Sensipar monopoly claims

3 December 2020 Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar off the market.

Americas

Fed Circuit split over $235m skinny label verdict

10 August 2021 The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.

More on this story

Americas

Actavis and Teva sued over narcotic addiction generic

1 March 2017 Speciality pharmaceutical company Orexo has filed a complaint against Actavis and its parent company Teva for infringing patents protecting Orexo’s Suboxone and Subutex.

Generics

Amgen, Teva to face Sensipar monopoly claims

3 December 2020 Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar off the market.

Americas

Fed Circuit split over $235m skinny label verdict

10 August 2021 The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.

More on this story

Americas

Actavis and Teva sued over narcotic addiction generic

1 March 2017 Speciality pharmaceutical company Orexo has filed a complaint against Actavis and its parent company Teva for infringing patents protecting Orexo’s Suboxone and Subutex.

Generics

Amgen, Teva to face Sensipar monopoly claims

3 December 2020 Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar off the market.

Americas

Fed Circuit split over $235m skinny label verdict

10 August 2021 The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

USPTO clarifies AI's role in patent eligibility

Fed Circ to rehear $235m ‘skinny label’ case

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features